These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 15665710)

  • 21. Effect of prenatal zidovudine on disease progression in perinatally HIV-1-infected infants.
    de Souza RS; Gómez-Marín O; Scott GB; Guasti S; O'Sullivan MJ; Oliveira RH; Mitchell CD
    J Acquir Immune Defic Syndr; 2000 Jun; 24(2):154-61. PubMed ID: 10935691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
    Connor EM; Sperling RS; Gelber R; Kiselev P; Scott G; O'Sullivan MJ; VanDyke R; Bey M; Shearer W; Jacobson RL
    N Engl J Med; 1994 Nov; 331(18):1173-80. PubMed ID: 7935654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Point-of-care capillary blood lactate measurements in human immunodeficiency virus-uninfected children with in utero exposure to human immunodeficiency virus and antiretroviral medications.
    Crain MJ; Williams PL; Griner R; Tassiopoulos K; Read JS; Mofenson LM; Rich KC;
    Pediatr Infect Dis J; 2011 Dec; 30(12):1069-74. PubMed ID: 22051859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.
    Moodley D; Moodley J; Coovadia H; Gray G; McIntyre J; Hofmyer J; Nikodem C; Hall D; Gigliotti M; Robinson P; Boshoff L; Sullivan JL;
    J Infect Dis; 2003 Mar; 187(5):725-35. PubMed ID: 12599045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 1998 Jan; 47(RR-2):1-30. PubMed ID: 9461044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Transmission Study Group.
    Cooper ER; Nugent RP; Diaz C; Pitt J; Hanson C; Kalish LA; Mendez H; Zorrilla C; Hershow R; Moye J; Smeriglio V; Fowler MG
    J Infect Dis; 1996 Dec; 174(6):1207-11. PubMed ID: 8940210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. Women and Infants Transmission Study Group.
    Moye J; Rich KC; Kalish LA; Sheon AR; Diaz C; Cooper ER; Pitt J; Handelsman E
    J Pediatr; 1996 Jan; 128(1):58-69. PubMed ID: 8551422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of human immunodeficiency virus-infected pregnant women at Latin American and Caribbean sites.
    Read JS; Cahn P; Losso M; Pinto J; Joao E; Duarte G; Cardoso E; Freimanis-Hance L; Stoszek SK;
    Obstet Gynecol; 2007 Jun; 109(6):1358-67. PubMed ID: 17540808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children < or = 5 years of age, Pediatric Spectrum of HIV Disease project (PSD), USA.
    Dominguez K; Bertolli J; Fowler M; Peters V; Ortiz I; Melville S; Rakusan T; Frederick T; Hsu H; D'Almada P; Maldonado Y; Wilfert C;
    Ann N Y Acad Sci; 2000 Nov; 918():236-46. PubMed ID: 11131710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
    ; de Vincenzi I
    Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mortality in the first 2 years among infants born to human immunodeficiency virus-infected women in Harare, Zimbabwe.
    Zijenah L; Mbizvo MT; Kasule J; Nathoo K; Munjoma M; Mahomed K; Maldonado Y; Madzime S; Katzenstein D
    J Infect Dis; 1998 Jul; 178(1):109-13. PubMed ID: 9652429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High Burden of Morbidity and Mortality but Not Growth Failure in Infants Exposed to but Uninfected with Human Immunodeficiency Virus in Tanzania.
    Locks LM; Manji KP; Kupka R; Liu E; Kisenge R; McDonald CM; Aboud S; Wang M; Fawzi WW; Duggan CP
    J Pediatr; 2017 Jan; 180():191-199.e2. PubMed ID: 27829511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group.
    Welles SL; Pitt J; Colgrove R; McIntosh K; Chung PH; Colson A; Lockman S; Fowler MG; Hanson C; Landesman S; Moye J; Rich KC; Zorrilla C; Japour AJ
    AIDS; 2000 Feb; 14(3):263-71. PubMed ID: 10716502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of intensive nurse case management in decreasing vertical transmission of human immunodeficiency virus infection in Wisconsin.
    Havens PL; Cuene BE; Hand JR; Gern JE; Sullivan BW; Chusid MJ
    Pediatr Infect Dis J; 1997 Sep; 16(9):871-5. PubMed ID: 9306482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Growth of infants born to HIV-infected women in South Africa according to maternal and infant characteristics.
    Venkatesh KK; Lurie MN; Triche EW; De Bruyn G; Harwell JI; McGarvey ST; Gray GE
    Trop Med Int Health; 2010 Nov; 15(11):1364-74. PubMed ID: 20955499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Missed opportunities for perinatal HIV prevention among HIV-exposed infants born 1996-2000, pediatric spectrum of HIV disease cohort.
    Peters V; Liu KL; Dominguez K; Frederick T; Melville S; Hsu HW; Ortiz I; Rakusan T; Gill B; Thomas P
    Pediatrics; 2003 May; 111(5 Pt 2):1186-91. PubMed ID: 12728136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study.
    Lorenzi P; Spicher VM; Laubereau B; Hirschel B; Kind C; Rudin C; Irion O; Kaiser L
    AIDS; 1998 Dec; 12(18):F241-7. PubMed ID: 9875571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurologic status of human immunodeficiency virus 1-infected infants and their controls: a prospective study from birth to 2 years. Mothers and Infants Cohort Study.
    Belman AL; Muenz LR; Marcus JC; Goedert JJ; Landesman S; Rubinstein A; Goodwin S; Durako S; Willoughby A
    Pediatrics; 1996 Dec; 98(6 Pt 1):1109-18. PubMed ID: 8951261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of human immunodeficiency virus-infected maternal environment on development of infant interleukin-12 production.
    Chougnet C; Kovacs A; Baker R; Mueller BU; Luban NL; Liewehr DJ; Steinberg SM; Thomas EK; Shearer GM
    J Infect Dis; 2000 May; 181(5):1590-7. PubMed ID: 10823758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune parameters and morbidity in hard drug and human immunodeficiency virus-exposed but uninfected infants.
    Neu N; Leighty R; Adeniyi-Jones S; Diaz C; Handelsman E; Kaufman G; Paul ME; Rich K; Mofenson L; Pitt J;
    Pediatrics; 2004 May; 113(5):1260-6. PubMed ID: 15121939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.